Marlene Leuenberger has been appointed general manager of Catalent Pharma Solutions’ Somerset, NJ drug development center of excellence.
 
Ms. Leuenberger has more than 25 years of management experience in engineering, quality operations and plant management within the biotech and pharmaceutical industry. She joins the company from Impax Laboratories, where she was general manager and senior director of Operations for its Middlesex, NJ facility. She has also held senior positions in operations at LTS Lohmann Therapy Systems Corp., Novartis Consumer Health, Wyeth (now Pfizer), and Procter and Gamble.
 
“I am delighted to welcome Marlene to Catalent and I am confident that her experience and expertise will complement our efforts in refocusing the site to become our East Coast center of excellence for the formulation and development of important drug compounds,” said Jonathan Arnold, president of Oral Drug Delivery at Catalent. “Along with her technical and leadership experience, Marlene embodies our patient first philosophy.”
 
Catalent recently invested in the Somerset facility to create a new drug development center of excellence focused on preclinical to clinical phase IIb formulation, analytical, and manufacturing solutions for orally delivered small molecules. Catalent also recently agreed to acquire Juniper Pharmaceuticals, including its Nottingham, U.K.-based Juniper Pharma Services division. When combined with Catalent’s existing drug development and manufacturing capabilities in the U.S. and Europe, the acquisition will expand Catalent’s offerings in formulation development, bioavailability solutions and clinical-scale oral dose manufacturing, and will complement its integrated global clinical and commercial supply network.